title: Perindopril for the prevention of atrial fibrillation recurrence after radiofrequency catheter ablation: One-year experience.
abstract: Recurrence of atrial fibrillation (AF) after ablation is still high. Perindopril plays an essential role in AF induction and maintenance.
  
  
  
  We aimed to prove that perindopril (8 mg) could prevent recurrence after pulmonary vein isolation.
  
  
  
  Patients with paroxysmal AF who received radiofrequency ablation were randomized to a 3-month course of perindopril 8 mg once daily (perindopril group) or placebo (placebo group). Angiotensin-II (Ang-II) therapy and standard transthoracic echocardiography were performed. All 256 patients with paroxysmal AF who received radiofrequency ablation were randomized. And we followed them for complete 1 year. The 3-month recurrence and the 1-year recurrence were compared between the 2 groups.
  
  
  
  The 3-month recurrence of AF was observed in 33 (26.19%) of 126 patients in the placebo group vs 19 (14.62%) of 130 patients who received perindopril 8 mg once daily (χ2, P = .021). One-year recurrence of AF was observed in 36 (28.5%) of 126 patients in the placebo group as compared with 21 (16.2%) of 130 patients who received perindopril after 1 year (P = .017). The κ value was 0.94 in the control group (P < .001) and 0.96 in the perindopril group (P < .001) between 3-month and 1-year recurrence. The Ang-II level was related to the left atrial distance with the reduction in AF recurrence (r = 0.17, P = .005 at 3 months; r = 0.25, P < .001 at 1 year).
  
  
  
  Perindopril is an effective and safe treatment for the prevention of AF recurrence after radiofrequency catheter ablation. This effect seems to be strongly associated with a significant decrease in Ang-II level and left atrial distance.
authors.affiliation: Division of Cardiology and.
authors.forename: Qiqi
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Division of Cardiology and.
authors.forename: Yunpeng
authors.initials: Y
authors.lastname: Shang
authors.affiliation: Division of Cardiology and.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Division of Cardiology and.
authors.forename: Dongchen
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Division of Anesthesiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Fengqin
authors.initials: F
authors.lastname: Dong
authors.affiliation: Division of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Yuangang
authors.initials: Y
authors.lastname: Qiu
authors.affiliation: Division of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Shangcai Village, Ouhai District, Wenzhou, Zhejiang Province, People's Republic of China.
authors.forename: Haiying
authors.initials: H
authors.lastname: Li
authors.affiliation: Division of Cardiology and. Electronic address: gogo-home@163.com.
authors.forename: Liangrong
authors.initials: L
authors.lastname: Zheng
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods; D004452:Echocardiography / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000008:administration & dosage / Q000009:adverse effects; D011183:Postoperative Complications / Q000175:diagnosis / Q000517:prevention & control*; D011667:Pulmonary Veins / Q000601:surgery*; D055502:Secondary Prevention / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril
keywords: Ablation; Atrial fibrillation; Perindopril; Recurrence